Alseres Pharmaceuticals (Alseres Pharmaceuticals) Cash-to-Debt : 0.02 (As of Jun. 2014)

View and export this data going back to . Start your Free Trial

What is Alseres Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Alseres Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2014 was 0.02.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Alseres Pharmaceuticals couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2014.

The historical rank and industry rank for Alseres Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

ALSE's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.49
* Ranked among companies with meaningful Cash-to-Debt only.

Alseres Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Alseres Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Alseres Pharmaceuticals Cash-to-Debt Chart

Alseres Pharmaceuticals Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Cash-to-Debt

Get a 7-Day Free Trial

0.01

0.04

Alseres Pharmaceuticals Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
Cash-to-Debt	Get a 7-Day Free Trial															-	-	0.04	0.03	0.02

Competitive Comparison of Alseres Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Alseres Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alseres Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alseres Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Alseres Pharmaceuticals's Cash-to-Debt falls into.

Alseres Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Alseres Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2013 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.311	/	(0	+	7.82)
	=	0.04

Alseres Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Jun. 2014 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.187	/	(0.119	+	8.297)
	=	0.02

Alseres Pharmaceuticals (OTCPK:ALSE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Alseres Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Alseres Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alseres Pharmaceuticals Inc (OTCPK:ALSE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Grove Street, Suite 2-400, Auburndale, MA, USA, 02466

Website

http://www.alseres.com

Alseres Pharmaceuticals Inc is a US-based biotechnology company. It is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system. The company's lead product candidate is Altropane, a proprietary molecular imaging agent which is used to diagnose Parkinson's disease and dementia. Further, it is focused on entering into partnerships to ensure development and commercialization of its product. Geographically the firm carries out its business through the region of United States.

Executives

Mark Jerome Pykett	officer: President and COO	223A MAIN ST, BOXFORD MA 021921
Robert Langer	director	98 MONTVALE RD, NEWTON MA 02459
Peter G Savas	director, officer: Chief Executive Officer	110 HARTWELL AVENUE, LEXINGTON MA 02173
John T Preston	director	C/O MOLTEN METAL TECHNOLOTY INC, 400-2 TOTTEN POND ROAD, WALTHAM MA 02154
Rice Kenneth L Jr	officer: Exec VP of Fin & Admin & CFO	C/O 85 MAIN STREET, HOPKINTON MA 01748
Joseph P Hernon	officer: Chief Financial Officer	1607 PONCE DE LEON AVENUE, SUITE 407, SAN JUAN PR 00909
Stephen M Peck	director	P O BOX 554, 3600 S LAKE DRIVE, ST FRANCIS WI, MILWAUKEE WI 53201-0554

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Headlines

From GuruFocus

Alseres Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-16-2009

Alseres Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 05-15-2009

Alseres Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 08-14-2009